Sun Biomedical, a biotechnology company with assets in the area of occupational drug testing, has entered into a manufacturing service agreement with Hangzhou Beichi Tech Co. (Beichi).
The company said in a statement that the agreement covers production of first models of the modified device (Oraline) as well as process optimisation, and further tune-up of Oraline new product.
The new models will be produced using HIPS-FOOD GRADE plastic, in accordance with agreed specifications. This agreement follows successful prototyping and testing of a new strip and housing modifications of new version of Oraline product at Beichi facilities.
This agreement is the first step towards a strategic manufacturing alliance between the companies and should provide Sun Biomedical with significant commercial advantages such as reduced product development time, reduced cost of goods and access to Beichi’s expertise in the field of medical diagnostic tests.
“Beichi is a highly respected company led by professionals with deep experience in the manufacture of medical diagnostic tests and reagents required for the production of Oraline" said Howard Digby, Executive Chairman of Sun Biomedical Ltd.